DE60226896D1 - Herstellung von f(ab')2 fragmenten in saügetierzelle - Google Patents

Herstellung von f(ab')2 fragmenten in saügetierzelle

Info

Publication number
DE60226896D1
DE60226896D1 DE60226896T DE60226896T DE60226896D1 DE 60226896 D1 DE60226896 D1 DE 60226896D1 DE 60226896 T DE60226896 T DE 60226896T DE 60226896 T DE60226896 T DE 60226896T DE 60226896 D1 DE60226896 D1 DE 60226896D1
Authority
DE
Germany
Prior art keywords
fragments
preparation
tissue cell
antibody fragments
bivalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60226896T
Other languages
English (en)
Inventor
Abraham Bout
David Halford Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Application granted granted Critical
Publication of DE60226896D1 publication Critical patent/DE60226896D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60226896T 2001-12-17 2002-12-17 Herstellung von f(ab')2 fragmenten in saügetierzelle Expired - Lifetime DE60226896D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL0100917 2001-12-17
PCT/NL2002/000841 WO2003051927A2 (en) 2001-12-17 2002-12-17 Production of f(ab')2 fragments in mammalian cells

Publications (1)

Publication Number Publication Date
DE60226896D1 true DE60226896D1 (de) 2008-07-10

Family

ID=19760784

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226896T Expired - Lifetime DE60226896D1 (de) 2001-12-17 2002-12-17 Herstellung von f(ab')2 fragmenten in saügetierzelle

Country Status (11)

Country Link
US (2) US20050048038A1 (de)
EP (1) EP1456238B1 (de)
AT (1) ATE397019T1 (de)
AU (1) AU2002353662B2 (de)
CA (1) CA2470579C (de)
DE (1) DE60226896D1 (de)
DK (1) DK1456238T3 (de)
ES (1) ES2307807T3 (de)
NZ (1) NZ533332A (de)
SI (1) SI1456238T1 (de)
WO (1) WO2003051927A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
SI1456238T1 (sl) 2001-12-17 2008-08-31 Crucell Holland Bv Proizvodnja f(ab)2 fragmentov v sesalskih celicah
EP1623023B1 (de) 2003-05-09 2008-11-12 Crucell Holland B.V. Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
WO2019070108A1 (es) 2017-10-02 2019-04-11 Laboratorios Silanes S.A. De C.V. Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos
WO2023205656A2 (en) * 2022-04-18 2023-10-26 John Paul Ii Medical Research Institute Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2116774C (en) * 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
EP1533380B1 (de) * 1999-04-15 2009-11-04 Crucell Holland B.V. Verwendung von Rekombinanten Proteinen in Menschlichen Zellen
EP1103610A1 (de) * 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
EP1130099A1 (de) * 2000-02-25 2001-09-05 Crucell Holland B.V. Aktiviertes Vitronektin als Angiogenesemarker nachgewiesen durch Phagen-Antikörper
SI1456238T1 (sl) 2001-12-17 2008-08-31 Crucell Holland Bv Proizvodnja f(ab)2 fragmentov v sesalskih celicah

Also Published As

Publication number Publication date
EP1456238B1 (de) 2008-05-28
EP1456238A2 (de) 2004-09-15
WO2003051927A3 (en) 2003-11-20
ES2307807T3 (es) 2008-12-01
SI1456238T1 (sl) 2008-08-31
CA2470579A1 (en) 2003-06-26
US20080166767A1 (en) 2008-07-10
WO2003051927A2 (en) 2003-06-26
NZ533332A (en) 2005-07-29
ATE397019T1 (de) 2008-06-15
AU2002353662A1 (en) 2003-06-30
AU2002353662B2 (en) 2009-04-23
CA2470579C (en) 2012-03-06
US7537916B2 (en) 2009-05-26
US20050048038A1 (en) 2005-03-03
DK1456238T3 (da) 2008-08-18

Similar Documents

Publication Publication Date Title
TR200001946T2 (tr) Aşı
FR15C0055I2 (fr) Feuillets de l'epithelium corneen humain reconstitues in vitro et methode de production de ces derniers
BR9910251A (pt) Estimulação hematopoiética
BR9709829A (pt) Formas de dosagem biconvexas de rápida desintegração
BR0009964A (pt) Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial
DE60226896D1 (de) Herstellung von f(ab')2 fragmenten in saügetierzelle
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
DK0977874T3 (da) Svækket salmonella-stamme anvendt som bæremedium til oral immunisering
ATE246681T1 (de) Sulfonamide
DE60216959D1 (de) Sich in schlagende kardiomyozyten verwandelnde stammzellen
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
ATA165999A (de) Medium zur protein- und serumfreien kultivierung von zellen
DE60037450D1 (de) Funf-helix protein
MX9710479A (es) Extracto de iridaceas y composiciones que la contienen.
ES2147720T3 (es) Factor de celulas madre.
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
BR0112070A (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
BR0312693A (pt) Células indutoras de aceitação de transplante de origem monocìtica e sua preparação e aplicação
PT1200561E (pt) Clone celular recombinante estavel, sua producao e utilizacao
AU2001258373A1 (en) Method for identifying helicobacter antigens
BR0110069A (pt) Combinações de substâncias ativas com propriedades inseticidas e acaricidas
DK1204659T3 (da) Serotonerge benzofuraner
TR200401462T4 (tr) Torsemid modifikasyonu II' yi içeren dengeli bir farmasötik formülasyonu
DK1343369T3 (da) Konservering af celler
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker

Legal Events

Date Code Title Description
8364 No opposition during term of opposition